Health and Fitness Health and Fitness
Fri, December 5, 2008
[ Fri, Dec 05th 2008 ] - Market Wire
FDA Advisory Committee to Discuss Genzyme s Synvisc-One PMA on Tuesday
[ Fri, Dec 05th 2008 ] - Market Wire
Candela to Seek Stockholder Approval Prior to Certain Issuances of Preferred Stock
[ Fri, Dec 05th 2008 ] - Market Wire
Cytokinetics, Inc.: Cytokinetics Announces Precli .. a Regarding Ispinesib to Be Presented at the 31st
[ Fri, Dec 05th 2008 ] - Market Wire
St. Jude Medical Announces Neuromodulation Divisi .. rand Identity at 12th Annual North American Neuro
[ Fri, Dec 05th 2008 ] - Market Wire
Resumen: Publicados en el New England Journal of .. an la eficacia de Viread en el tratamiento de la
Thu, December 4, 2008
[ Thu, Dec 04th 2008 ] - Market Wire
PDL BioPharma, Inc.: David Parkinson, M.D. Elected to Facet Biotech's Board of Directors
[ Thu, Dec 04th 2008 ] - Market Wire
NitroMed Receives Unsolicited Acquisition Proposal from Deerfield Management
[ Thu, Dec 04th 2008 ] - Market Wire
AmSurg Corp. to Present at the RBC Capital Markets 2008 Healthcare Conference
[ Thu, Dec 04th 2008 ] - Market Wire
Assisted Living Concepts, Inc.: Assisted Living C .. pts, Inc. to Attend New York Investor Conferences
[ Thu, Dec 04th 2008 ] - Market Wire
SCOR: Moody's upgrades SCOR to 'A2'
[ Thu, Dec 04th 2008 ] - Market Wire
Alnylam Selected as 2009 Technology Pioneer by the World Economic Forum
[ Thu, Dec 04th 2008 ] - Market Wire
Jonathan Lewis, MD, PhD, Appointed to Scientific .. ory Council of the Hope Funds for Cancer Research
[ Thu, Dec 04th 2008 ] - Market Wire
Osiris Completes Enrollment in First Worldwide Phase III Stem Cell Trial
[ Thu, Dec 04th 2008 ] - Market Wire
Novelos Therapeutics and Academic Collaborators P .. Posters at 2008 AACR Tumor Immunology Conference
[ Thu, Dec 04th 2008 ] - Market Wire
Tesetaxel, a Leading Oral Taxane in Clinical Deve .. ation as an Orphan Drug for Treatment of Patients
[ Thu, Dec 04th 2008 ] - Market Wire
Hi-Tech Pharmacal to Release First Quarter Earnings and Hold Conference Call on December 9, 2008
[ Thu, Dec 04th 2008 ] - Market Wire
BioSante Pharmaceuticals Signs Elestrin " Marketing Agreement with Azur Pharma
[ Thu, Dec 04th 2008 ] - Market Wire
ImmunoGen, Inc. Announces Webcast of Panel Sessio .. he RBC Capital Markets 2008 Healthcare Conference
[ Thu, Dec 04th 2008 ] - Market Wire
Sirona Announces $50 Million Share Repurchase Authorization
[ Thu, Dec 04th 2008 ] - Market Wire
Centene Corporation Names Aaron W. Brace as President and CEO of South Carolina Subsidiary
Wed, December 3, 2008
[ Wed, Dec 03rd 2008 ] - Market Wire
AngioDynamics Implements Leadership Development P .. eliminary Fiscal Second Quarter Financial Results
[ Wed, Dec 03rd 2008 ] - Market Wire
Alphatec Spine to Present at the RBC Healthcare Conference
[ Wed, Dec 03rd 2008 ] - Market Wire
Biomoda, Inc.: NM Tech, Biomoda Win Legislative Support for Lung Cancer Screening
[ Wed, Dec 03rd 2008 ] - Market Wire
Zila to Report Fiscal 2009 First Quarter Financia .. s and Host Investor Conference Call on December 8
[ Wed, Dec 03rd 2008 ] - Market Wire
PerkinElmer Announces Strategic Acquisition of Arnel Inc.
[ Wed, Dec 03rd 2008 ] - Market Wire
CytoDyn Awarded Global Patents For Modernizing The Treatment of Infectious Diseases
[ Wed, Dec 03rd 2008 ] - Market Wire
Aspect Medical Systems Repurchases $35 Million of Its 2.5% Convertible Senior Notes Due 2014
[ Wed, Dec 03rd 2008 ] - Market Wire
Synta Pharmaceuticals to Participate in the RBC Capital Markets Healthcare Conference
[ Wed, Dec 03rd 2008 ] - Market Wire
Health Net Federal Services Is Awarded URAC Healt .. on Management and Case Management Reaccreditation
[ Wed, Dec 03rd 2008 ] - Market Wire
Somaxon Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference

Somaxon Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference


Published on 2008-12-03 08:07:49 - Market Wire
  Print publication without navigation


SAN DIEGO--([ BUSINESS WIRE ])--Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) today announced that Richard Pascoe, president and chief executive officer, will participate in a panel discussion at the RBC Capital Markets Healthcare Conference at the Westin Times Square Hotel in New York, on Wednesday, December 10, 2008 at 2:30 p.m. ET (11:30 a.m. PT).

A live webcast of the presentation will be available in the Investor Relations section of the company's website under Event Scheduler at [ www.somaxon.com ]. The webcast will be archived and accessible for at least 14 days.

About Somaxon Pharmaceuticals

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. A New Drug Application (NDA) for Silenor® (doxepin), Somaxon's drug candidate for insomnia, has been filed with the U.S. Food and Drug Administration and currently is under review.

For more information, please visit the company's web site at [ www.somaxon.com ].

Contributing Sources